Skip to main content

Pitfalls of FDA’s Breakthrough Drug Program

Posted in News on 4.17.2018

While the FDA’s expedited review programs are often touted as a way of speedily getting life-saving or life-altering drugs into the hands of patients in need, some experts, among them Alosa Health founder Jerry Avorn, are skeptical about the FDA’s breakthrough drug therapy (BTD) program....


JAMA Study Challenges Efficacy of Opioids vs Non-addictive Alternatives

Posted in News on 3.21.2018

For some time now the medical community has sought guidance on responsible prescribing related to opioids. A large, randomized trial, recently published in JAMA, demonstrated that for patients with moderate-to-severe chronic back pain or hip or knee osteoarthritis pain, a non-opioid medication regim...


Psychology of Clinical Decision Making

Posted in News on 2.26.2018

In a Perspective piece published earlier this week in the New England Journal, Alosa Health Founder and Clinical Advisor Dr. Jerry Avorn discusses the science of decision-making. While the science of decision-making is a well-developed field, its application to the field of medicine has been slow. ...


Talking to Patients About Health Policy

Posted in News on 12.14.2017

Alosa Health founder and clinical consultant Dr. Jerry Avorn offered an opinion in the Journal of the Medical American Association’s (JAMA’s) essay feature on the topic of engaging patients in health policy talk.   The question of whether clinicians should interact with their ...


Academic Detailing to Combat Opioids in Northern California

Posted in News on 11.17.2017

Kasier Health News recently reported that money from Obama-era grants is being used to fund academic detailing programs in California for the purpose of educating providers on the risks of prescribing opioids. To date, academic detailing programs has been used to address overprescribing of opioids a...


Pharmaco-Epi Community Responds to New Study

Posted in News on 9.15.2017

Pin pointing the dollar amount that it actually costs to bring a drug to market is a tricky business. Until recently, the most widely accepted estimate has come from Tufts Center for the Study of Drug Development, at $2.7 billion per drug.  Yet a new study published in JAMA places that number ...


With Drug Resistance, Prevention and Early Detection is Key

Posted in News on 7.13.2017

A news release from the World Health Organization (WHO) stated that gonorrhea bacteria are evolving in a way that makes the infection much harder to treat. Gonorrhea is a sexually transmitted infection (STI) that is generally curable with antibiotics. However, new data from various countries around ...


Post Editorial Reflects on Progress in HIV/AIDs Treatment and Prevention

Posted in News on 7.12.2017

The Washington DC Department of Health HIV/AIDS, Hepatitis, STD, and TB Administration (HAHSTA) recently published its Annual Epidemiology & Surveillance Report with good news, as noted by the editorial staff of the Washington Post. The report shows substantial progress being made in the D.C. a...


What Assault on FDA Authority Means for Public Health

Posted in News on 5.11.2017

In a piece recently published in The American Prospect, Alosa Health founder Dr. Jerry Avorn discusses regulatory trends around drug manufacturing and marketing as well as their consequences, making the case that diminishing FDA authority could have harmful effects on patients.  Specifically, ...


FDA Review Process Speedier than European Counterpart

Posted in News on 4.6.2017

The FDA has been getting flack from the U.S. President as well as the president’s nominee to lead the agency, Dr. Scott Gottlieb, on account of their approvals process, which has been characterized as “slow and burdensome”. Yet, a recent study published in the New England Journal ...